Nuwellis, Inc. Announces Passage of Warrant Proposal
January 04 2023 - 5:24PM
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused
on transforming the lives of people with fluid overload, today
announced that the Company held its adjourned special meeting of
stockholders on January 4, 2023 at 2:00 p.m. (Central Time) (the
“Special Meeting”). At the time of the Special Meeting,
stockholders (i) approved the Warrant Proposal (as defined below)
and (ii) authorized one or more adjournments of the meeting of
stockholders to solicit additional proxies in the event there were
insufficient votes to approve the Warrant Proposal.
A total of 3,815,782 shares of the Company’s
common stock were present at the Special Meeting virtually or by
proxy, which represents approximately 36% of the shares of common
stock outstanding as of the record date for the Special
Meeting.
The results of the voting are shown below:
Proposal 1 - To approve pursuant to Nasdaq
Listing Rule 5635(d) and Nasdaq’s interpretations and guidance
thereunder, the issuance of up to 66,226,752 shares of the
Company’s common stock (as the same is to be adjusted for the
reverse stock split effectuated by the Company on December 9, 2022)
upon the exercise of its warrants issued to investors in its
underwritten offering that closed on October 18, 2022 (“October
2022 Underwritten Offering”) that may be equal to or exceed 20% of
the Company’s common stock outstanding before the October 2022
Underwritten Offering (the “Warrant Proposal”).
|
VOTES FOR |
VOTES AGAINST |
ABSTAIN |
|
|
1,955,994 |
1,791,220 |
68,568 |
|
Proposal 2 - To authorize one or more
adjournments of the stockholder meeting to solicit additional
proxies in the event there are insufficient votes to approve the
Warrant Proposal.
|
VOTES FOR |
VOTES AGAINST |
ABSTAIN |
|
|
1,971,645 |
1,746,660 |
97,477 |
|
The vote numbers above reflect share amounts as
of the meeting record date and are not adjusted for the reverse
stock split effectuated by the Company on December 9, 2022.
About NuwellisNuwellis, Inc.
(Nasdaq: NUWE) is a medical technology company dedicated to
transforming the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on commercializing the Aquadex SmartFlow® system for
ultrafiltration therapy. Nuwellis is headquartered in Minneapolis,
Minnesota, with a wholly owned subsidiary in Ireland.
About the Aquadex SmartFlow
SystemThe Aquadex SmartFlow system delivers clinically
superior therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow system is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
CONTACTS
INVESTORS:Vivian CervantesGilmartin Group
LLCir@nuwellis.com
MEDIA:Annika
ParrishHealth+Commerceannika@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024